CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19 (CARE BEAR-LC)

CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19 (CARE BEAR-LC): A Proof-of-Concept, Mechanistic Trial

The goal of this proof-of-concept clinical trial is to determine whether cardiac rehabilitation improves exercise capacity and chronotropic (heart rate) response to exercise among people with Long COVID. The study will include individuals with confirmed SARS-CoV-2 infection, symptoms not present prior to COVID-19 that are persistent for at least 3 months after acute infection ("Long COVID"), and who have reduced exercise capacity less than predicted and reduced heart rate response during cardiopulmonary exercise testing (CPET). In addition to the primary outcome of change in peak VO2, secondary outcomes will include change in symptoms including autonomic symptoms (COMPASS-31), anxiety (GAD-7), depression (PHQ-9), endothelial function with brachial artery flow-mediated dilation, and satisfaction (net-promotor score).

Study Overview

• Status: Recruiting
• Conditions: COVID-19; Long COVID
• Intervention / Treatment: Behavioral: Cardiac Rehabilitation

Detailed Description

Study Overview

This single-center, proof-of-concept mechanistic study of cardiac rehabilitation will use a pre-post design to establish whether there is any effect of cardiac rehabilitation on adjusted heart rate reserve achieved and peak oxygen consumption (peak VO2) in LC.

Once a participant is identified as potentially eligible, they will be contacted by the study team. Participants will be asked to co-enroll in the Long-term Impact of Infection with Novel Coronavirus observational cohort ("LIINC" NCT 04362150). If participants do not agree to be co-enrolled in LIINC (if they are not already included) and the Cardiovascular Sub-Study, they will not be allowed to enroll.

Participants will be consented by the PI or research team before any procedures take place. Participants who provide written informed consent and meet the inclusion criteria will be enrolled into the study. They undergo a series of baseline measurements as outlined in the Schedule of Events. They will participate in 12 weeks of cardiac rehabilitation and then undergo follow-up measurements to determine the safety, clinical impact, and biological impact of the therapy as outlined in the Schedule of Events.

Blood collection will occur at baseline and after completion of cardiac rehabilitation as per the Schedule of Events and will be timed to stay within Red Cross Guidelines (less than 480 mL every 8 weeks).

The details of the visit schedule are outlined below. Ultimately, the most up to date Schedule of Events will be the final guide for what events are to occur at each specific study visit.

Informed Consent

The study PI or their designee will explain the risks and benefits of the study and obtain written informed consent. Those who consent to participate in the study will undergo a Screening Assessment.

Screening Assessment

Assessments performed exclusively to determine eligibility for this study will be performed only after obtaining informed consent. Assessments performed for clinical indication (not exclusively to determine study eligibility) or other research studies may be used for screening even if the studies were performed before informed consent was obtained. For example, a screening cardiopulmonary exercise test may be used to establish eligibility that was performed through clinical practice or for research through the LIINC study or RECOVER. However, these measurements may be repeated at the discretion of the PI.

Following informed consent, study screening will occur during a period of one or more visits. The Screening Assessment will include a physical examination by a study clinician (physician, nurse, or physician assistant). Details of the participant's COVID-19 history will be reviewed and/or confirmed, and a symptom assessment will be performed.

Baseline Assessments

After consenting but prior to starting cardiac rehabilitation, all participants will undergo baseline assessments including symptom assessments, cardiopulmonary exercise testing and vascular function studies.

Intervention

Participants who screen into the study and complete baseline measurements will then start standard of care cardiac rehabilitation at University of California, San Francisco (UCSF) Parnassus Campus. Exercise prescriptions will be based on the heart rate performance during the baseline CPET. Standard clinical assessments will be made to tailor recommendations during the course of cardiac rehabilitation. The intensity of the exercise prescription and level of monitoring will be tailored to the individual participant's performance on their baseline CPET according to guidelines. Exercise will be prescribed by a Cardiac Exercise Physiologist in accordance with standard cardiac rehabilitation protocols. Resistance exercise activities will also be incorporated. Recumbent exercise will be utilized based on assessment by exercise physiologist and patient. Dietary counseling, smoking cessation counseling for smokers, and medication counseling will be incorporated according to standard cardiac rehabilitation protocols. Participants are asked to commit to attending at least 24 sessions, of which 12 (one per week for 12 weeks) must be in person at UCSF Parnassus. Participants will be allowed to select a fully in-person approach (36 sessions) or hybrid approach (12-24 in person, 12-24 virtual for up to 36 total sessions).

Duration of intervention: 12 weeks

Follow Up Assessments (Week 12) After completion of cardiac rehabilitation (approximately 12 weeks after start), participants will complete the follow up assessments within 2 weeks, which will include the same assessments as baseline as well as an assessment of satisfaction with cardiac rehabilitation as measured with the net-promotor score.

• Study Type: Interventional
• Enrollment (Anticipated): 25
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Matthew S Durstenfeld, MD MAS; Phone Number: 628-206-5562; Email: matthew.durstenfeld@ucsf.edu

Study Locations

• United States
  • California
    • San Francisco, California, United States, 94110
      • Recruiting
      • University of California, San Francisco
      • Contact: Matthew Durstenfeld, MD MAS; Phone Number: 628-206-5562; Email: matthew.durstenfeld@ucsf.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Age 18 years or older
2. Previously documented SARS-CoV-2 RNA positivity from an oral or nasal swab, as measured by a nucleic acid amplification test, documented positive antigen testing, or positive nucleocapsid antibody. Documentation of the positive test is required.
3. Presence of persistent symptoms, defined as at least one COVID-attributed symptom newly present during acute illness or worse than baseline and reported to still be present for at least 90 days following symptom onset. This will be ascertained using study case report forms.
4. Reduced exercise capacity <85% predicted and adjusted heart rate reserve achieved <80% on maximal CPET (RER>1.05). If there are difficulties with recruitment we may include individuals with exercise capacity between 85-99% predicted.
5. Willing and able to actively participate in cardiac rehabilitation including attending at least 12 in person sessions at UCSF Parnassus.
6. Agree to participate in the LIINC Study including the cardiovascular substudy if they are not already participating.

Exclusion Criteria:

1. Pregnant or intention to become pregnant during study
2. Pre-existing congenital heart disease, heart failure, pulmonary hypertension, heart or lung transplant, or cardiac valve surgery
3. Myocardial infarction, or coronary artery bypass graft surgery, or new diagnosis of heart failure with a reduced ejection fraction <40% within 90 days prior to enrollment (Class I indications for cardiac rehabilitation)
4. Acute myocarditis diagnosed <90 days prior
5. Atrial fibrillation, atrial flutter, or other arrhythmias requiring antiarrhythmic therapy
6. Use of beta-blockers, non-dihydropyridine calcium channel blockers or ivabradine
7. Implanted pacemaker or defibrillator
8. Chronic lung disease requiring the use of home oxygen therapy
9. Inability to ride a sitting bicycle for CPET
10. Severe post-exertional malaise or symptom worsening that would preclude participation in cardiac rehabilitation
11. Medical or psychological comorbidities that would prevent safe participation in the trial, in the opinion of the Principal Investigator

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Cardiac Rehabilitation; Participants will undergo 12 weeks of standard of care cardiac rehabilitation.

Behavioral: Cardiac Rehabilitation; Exercise prescriptions will be based on the heart rate performance during the baseline CPET. The intensity of the exercise prescription and level of monitoring will be tailored to the individual participant's performance on their baseline CPET according to guidelines. Exercise will be prescribed by a Cardiac Exercise Physiologist in accordance with standard cardiac rehabilitation protocols. Resistance exercise activities will also be incorporated. Recumbent exercise will be utilized based on assessment by exercise physiologist and patient. Dietary counseling, smoking cessation counseling for smokers, and medication counseling will be incorporated according to standard cardiac rehabilitation protocols. Participants are asked to commit to attending at least 24 sessions, of which 12 (one per week for 12 weeks) must be in person. Participants will be allowed to select a fully in-person approach (36 sessions) or hybrid approach (12-24 in person, 12-24 virtual for up to 36 total sessions).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in adjusted heart rate reserve	Adjusted heart rate reserve (peak HR-rest HR)/(220-age-rest HR) achieved during symptom-limited maximal cardiopulmonary testing performed with cycle ergometer	Baseline and 12 weeks
Change in Peak VO2 (ml/kg/min)	Peak VO2 measured with maximal symptom limited cardiopulmonary exercise testing	Baseline and 12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Peak VO2 (percent predicted)	Peak VO2 (percent predicted using the Wasserman equations) measured with maximal symptom limited cardiopulmonary exercise testing	Baseline and 12 weeks
Number of Cardiac Rehabilitation sessions attended	Number of in person and virtual sessions attended by each participant	12 weeks
Change in Proportion with peak VO2 less than 85% predicted	Proportion with peak VO2<85% predicted (using the Wasserman equations) measured with maximal symptom limited cardiopulmonary exercise testing	Baseline and 12 weeks
Change in Number of Long COVID symptoms	Long COVID symptoms assessed using the LIINC symptom questionnaire (number of symptoms, more symptoms is worse).	Baseline and 12 weeks
Change in Composite Autonomic Symptom Scale-31 (Compass 31) Score	Compass 31 summary score (0-100, with higher score indicating more severe autonomic symptoms).	Baseline and 12 weeks
Change in Patient Health Questionnaire-9 (PHQ-9) Score	The PHQ-9 is a self-administered diagnostic instrument for depression. The PHQ-9 score ranges from 0 to 21, with higher scores indicating more severe depression.	Baseline and 12 weeks
Change in Generalized Anxiety Disorder Screener (GAD-7) Score	The GAD-7 is a self-administered diagnostic instrument for depression. The GAD-7 score ranges from 0 to 27, with higher scores indicating more severe anxiety.	Baseline and 12 weeks
Change in Short Form Survey (SF-36) Score	Overall quality of life using the short form health survey (SF-36). Scores range from 0-100 with higher scores representing a more favorable health state. The 36 questions are combined to form 8 scales in the domains of physical functioning, role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional well-being, social functioning, pain, and general health.	Baseline and 12 weeks
Change in Quality of life assessed with EuroQol (EQ-5D) Visual Analogue Scale	Quality of life on EQ-5D VAS (0-100, with 100 being the best).	Baseline and 12 weeks
Change in flow mediated dilation of the brachial artery	Endothelial function assessed by change in brachial artery diameter in mm after administration of nitroglycerin compared to before administration of nitroglycerin	Baseline and 12 weeks
Change in Inflammation	hsCRP (mg/L) is a marker of inflammation	Baseline and 12 weeks
Net Promotor Score	Would you recommend cardiac rehabilitation to your family/friends (1-10 scale). The percentage who report 0-6 ("detractors") is subtracted from the percentage who report 9 or 10 ("promotors") to calculate a "Net Promoter Score."	12 weeks

Collaborators and Investigators

• Sponsor: University of California, San Francisco
• Investigators: Principal Investigator: Matthew S Durstenfeld, MD MAS, University of California, San Francisco

Study record dates

Study Major Dates

• Study Start (Anticipated): December 1, 2022
• Primary Completion (Anticipated): September 1, 2024
• Study Completion (Anticipated): September 1, 2024

Study Registration Dates

• First Submitted: September 2, 2022
• First Submitted That Met QC Criteria: September 2, 2022
• First Posted (Actual): September 7, 2022

Study Record Updates

• Last Update Posted (Actual): December 2, 2022
• Last Update Submitted That Met QC Criteria: November 29, 2022
• Last Verified: November 1, 2022

More Information

Terms related to this study

• Keywords: chronotropic incompetence; cardiac rehabilitation; cardiopulmonary exercise testing
• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19
• Other Study ID Numbers: 22-37106

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No